Inogen Inc (NASDAQ:INGN) Stock Position Raised by Redmond Asset Management LLC

Redmond Asset Management LLC lifted its position in Inogen Inc (NASDAQ:INGN) by 4.3% in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 23,227 shares of the medical technology company’s stock after acquiring an additional 954 shares during the quarter. Redmond Asset Management LLC owned approximately 0.11% of Inogen worth $1,551,000 as of its most recent filing with the SEC.

Several other large investors have also recently modified their holdings of the stock. Oregon Public Employees Retirement Fund lifted its position in shares of Inogen by 1.9% in the 1st quarter. Oregon Public Employees Retirement Fund now owns 7,029 shares of the medical technology company’s stock valued at $670,000 after acquiring an additional 132 shares in the last quarter. Arizona State Retirement System increased its stake in Inogen by 1.4% in the 1st quarter. Arizona State Retirement System now owns 12,845 shares of the medical technology company’s stock valued at $1,225,000 after buying an additional 178 shares during the period. Advisor Group Inc. increased its stake in Inogen by 71.4% in the 2nd quarter. Advisor Group Inc. now owns 461 shares of the medical technology company’s stock valued at $31,000 after buying an additional 192 shares during the period. Harel Insurance Investments & Financial Services Ltd. acquired a new position in Inogen in the 1st quarter valued at approximately $25,000. Finally, Mason Street Advisors LLC increased its stake in Inogen by 2.9% in the 1st quarter. Mason Street Advisors LLC now owns 9,512 shares of the medical technology company’s stock valued at $907,000 after buying an additional 267 shares during the period. Institutional investors and hedge funds own 98.63% of the company’s stock.

Several research analysts have weighed in on the stock. Stifel Nicolaus lowered shares of Inogen from a “buy” rating to a “hold” rating and dropped their price objective for the company from $85.00 to $48.00 in a research note on Wednesday, August 7th. Piper Jaffray Companies dropped their price objective on shares of Inogen from $140.00 to $80.00 and set an “overweight” rating on the stock in a research note on Wednesday, August 7th. Leerink Swann lowered shares of Inogen from an “outperform” rating to a “market perform” rating in a research note on Thursday, August 8th. BidaskClub lowered shares of Inogen from a “sell” rating to a “strong sell” rating in a research note on Friday, August 9th. Finally, Needham & Company LLC lowered shares of Inogen from a “buy” rating to a “hold” rating in a research note on Wednesday, August 7th. Three research analysts have rated the stock with a sell rating, six have issued a hold rating and one has given a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $82.17.

Shares of INGN traded up $0.08 during mid-day trading on Thursday, hitting $43.01. 4,112 shares of the company’s stock were exchanged, compared to its average volume of 669,274. The firm’s fifty day simple moving average is $59.21. Inogen Inc has a twelve month low of $41.19 and a twelve month high of $287.79. The firm has a market capitalization of $986.37 million, a PE ratio of 18.82, a price-to-earnings-growth ratio of 2.66 and a beta of 1.40. The company has a current ratio of 7.35, a quick ratio of 6.82 and a debt-to-equity ratio of 0.01.

Inogen (NASDAQ:INGN) last announced its quarterly earnings results on Wednesday, August 7th. The medical technology company reported $0.45 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.50 by ($0.05). Inogen had a return on equity of 13.34% and a net margin of 11.24%. The business had revenue of $101.10 million for the quarter, compared to analyst estimates of $106.88 million. During the same quarter last year, the company earned $0.65 EPS. The business’s revenue for the quarter was up 3.9% compared to the same quarter last year. As a group, equities research analysts forecast that Inogen Inc will post 1.09 EPS for the current year.

Inogen Company Profile

Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

Featured Article: What is the price-sales ratio?

Institutional Ownership by Quarter for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.